The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Table 3 Objective tumor response

	Induction therapy CapeOX + BEV (N = 52)		Maintenance therapy Capecitabin + BEV (N = 45)		Reintoroduction therapy CapeOX + BEV (N = 29)
	n	%	n	%	n	%
CR	0	0	0	0	2	6.9
PR	29	55.8	8	17.8	7	24.1
SD	21	40.4	28	62.2	17	58.6
PD	2	3.8	9	20.0	3	10.3
ORR, %	55.8		17.8		31.0
DCR, %	96.2		80.0		89.7

BEV bevacizumab, N total number of patients, n number of patients, CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate ([CR + PR]/N × 100), DCR disease control rate ([CR + PR + SD]/N × 100)

ISSN: 1471-2407